Remdesivir for the Treatment of Covid-19 — Preliminary Report | NEJM

Type Journal Article Author John H. Beigel Author Kay M. Tomashek Author Lori E. Dodd Author Aneesh K. Mehta Author Barry S. Zingman Author Andre C. Kalil Author Elizabeth Hohmann Author Helen Y. Chu Author Annie Luetkemeyer Author Susan Kline Author Diego Lopez de Castilla Author Robert W. Finberg Author Kerry Dierberg Author Victor Tapson Author Lanny Hsieh Author Thomas F. Patterson Author Roger Paredes Author Daniel A. Sweeney Author William R. Short Author Giota Touloumi Author David Chien Lye Author Norio Ohmagari Author Myoung-don Oh Author Guillermo M. Ruiz-Palacios Author Thomas Benfield Author Gerd Fätkenheuer Author Mark G. Kortepeter Author Robert L. Atmar Author Buddy Creech Author Jens Lundgren Author Abdel G. Babiker Author Sarah Pett Author James D. Neaton Author Timothy H. Burgess Author Tyler Bonnett Author Michelle Green Author Mat Makowski Author Anu Osinusi Author Seema Nayak Author H. Clifford Lane URL https://www.nejm.org/doi/10.1056/NEJMoa2007764 Publication The New England Journal of Medicine (NEJM) Date 22/05/2020 DOI DOI: 10.1056/NEJMoa2007764 Accessed 2020-07-05 20:10:07 Abstract Background Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), none have yet been shown to be efficacious. Methods We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults hospitalized with Covid-19 with evidence of lower respiratory tract involvement. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only.